Please assess the completion status of the following clinical trial:

Trial Title: Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven, locally advanced stage III-IV A-B (UICC 2002) primary squamous cell carcinoma of the oral cavity, the oropharynx, the hypopharynx, the supraglottic larynx~* Age ≥ 18~* Written informed consent for the participation in the clinical trial~Exclusion Criteria:~* Inadequate hepatic function: Bilirubin \> 2,0 mg/dl, SGOT, SGPT, AP, Gamma-GT \> 3 x ULN~* Inadequate bone marrow function: leukocytes \< 3,5 x 10\^9/l, platelets \< 100 x 10\^9/l or neutrophils \< 1,5 x 10\^9/l~* Serum creatinine \> 1,5 mg/dl, creatinine clearance \< 60ml/min~* Uncontrolled severe somatic or psychological disease: e.g. unstable angina pectoris; myocardial infarction during the last 6 months; significant cardial rhythm disorders; apoplexy; high grade stenosis of the carotis; neurological or psychiatric disorders including convulsive disorders; dementia; psychosis; active uncontrolled infection or sepsis; liver cirrhosis; Child stage B,C; severe liver function disorders; marginal changes in the blood count; severe kidney damage; HIV-infection~* Acute infections~* Fertile women without adequate contraception during and up to 6 months after therapy (the method of contraception has to be high effective as described in the Note for guidance on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals (CPMP/ICH/286/95 mod) and it has to be discussed with the investigator)~* Pregnant or breast feeding women~* Men, who are not willing to use adequate contraception during and up to 6 months after therapy, that is discussed with the investigator~* ECOG-Status \> 1~* Reduced hearing function (especially higher frequencies)~* Exsiccosis~* Neuropathy, caused by cisplatin~* Concurrent malignancies, with exception of adequately treated basal cell carcinoma of the skin or in situ carcinoma or the cervix~* Prior radiotherapy of the neck or chemotherapy~* Distant metastasis~* Recurrent carcinoma in the head and neck region~* Prior neck-dissection or surgical intervention exceeding an exploratory excision~* Known intolerance to 5-Fluorouracil~* Known deficit of Dihydropyrimidine dehydrogenase (DPD)~* Simultaneous therapy with Brivudin or other inhibitors of DPD~* Known intolerance to Cisplatin or other substances that contain platin~* Known intolerance to Paclitaxel or one of the included substances, especially to Poly(oxyethylene)Rhizinusöl/Macrogolglycerol ricinoleate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reduced RT + Pacitaxel/Cisplatin (Type: EXPERIMENTAL): 63,6 Gy accelerated hyperfractionated radiotherapy with Paclitaxel (20mg/m\^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m\^2/d) on days 1-4 and 29-32, followed by a salvage operation or neck dissection if there is persisting tumor
- Standard RT + 5-Fluorouracil/Cisplatin (Type: ACTIVE_COMPARATOR): 70,6 Gy accelerated hyperfractionated radiotherapy with 5-Fluorouracil(600mg/m\^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m\^2/d) on days 1-5 and 29-33, followed by a salvage operation or neck dissection if there is persisting tumor

Based on this trial design, predict the completion outcome and termination type (if applicable).